RCUS — Arcus Biosciences Share News
0.000.00%
Last trade - 00:00- $2.91bn
- $2.30bn
- $247.00m
U.S. STOCKS ON THE MOVE-3M, VF Corp, SiriusXM
U.S. STOCKS ON THE MOVE-Howmet Aerospace, Alaska Air, Arcus Biosciences
Arcus Biosciences falls after H.C. Wainwright initiates with 'neutral' rating
Brief: Arcus Biosciences Announces Clinical Trial Collaboration Agreement To Evaluate Casdatifan In Combination With Volrustomig In Renal Cell Carcinoma
U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla
Brief: Taiho Pharmaceutical Exercises Option For An Exclusive License To Quemliclustat In Japan And Certain Territories In Asia
U.S. STOCKS ON THE MOVE-Golar LNG, gold miners, Big Tech
U.S. STOCKS ON THE MOVE-Golar LNG, gold miners, Big Tech
U.S. STOCKS ON THE MOVE-Macy's, Niu, crypto stocks
Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial
Brief: Arcus Biosciences Completes Patient Enrollment In Phase 3 Trial Evaluating A Domvanalimab-Containing Regimen In First-Line Metastatic Upper GI Cancers
Brief: Gilead And Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced The Risk Of Death In Third-Line Metastatic Colorectal Cancer
Brief: Gilead And Arcus Announce Anti-Tigit Domvanalimab Plus Zimberelimab And Chemotherapy Exceeded One Year Of Median Progression-Free Survival As A First-Line Treatment For Upper Gi Cancers
Health Rounds: Experimental treatment slows advanced colon cancer, improves survival in trial
Arcus Biosciences Inc expected to post a loss of 95 cents a share - Earnings Preview
Brief: Arcus Biosciences Inc Files For Shelf Of Up To 16.2 Million Shares - SEC Filing
Arcus Biosciences Inc expected to post a loss of $1.02 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Hanover Insurance, Lincoln National, Transdigm Group
U.S. STOCKS ON THE MOVE-Kura Oncology , Vertex Pharma, Nucor